Paclitaxel, Cisplatin, and Concurrent Radiation for Esophageal Cancer

REFERENCES

• Hesketh P. J., Clapp R. W., Doos W. G., et al. The Increasing Frequency of Adenocarcinoma of the Esophagus. Cancer 1989; 64: 526–530
   PubMed Web of Science ®Google Scholar
• Blot W. J., Devesa S. S., Kneller R. W., et al. Rising Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia. JAMA 1989; 265: 1287–1289
   Web of Science ®Google Scholar
• Walsh T. N., Noonan N., Hollywood D., et al. A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma. N. Engl. J. Med. 1996; 335: 462–467
   PubMed Web of Science ®Google Scholar
• Urba S., Orringer M., Turrisi A., et al. A Randomized Trial Comparing Surgery (S) to Preoperative Concomitant Chemoradiation Plus Surgery in Patients (Pts) with Resectable Esophageal Cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: 277a
   Google Scholar
• Ajani J. A., Ilson D., Dougherty K., et al. Activity of Taxol in Patients with Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus. Uses of Progesterone in Clinical Practice. J. Natl. Cancer Inst. 1994; 86: 1086–1091
   PubMed Web of Science ®Google Scholar
• Choy H., Rodriguez F. F., Koester S., et al. Investigation of Taxol as a Potential Radiation Sensitizer. Cancer 1993; 71: 3774–3778
   PubMed Web of Science ®Google Scholar
• Sinclair W. K., Morton R. A. X-ray Sensitivity During the Cell Generation Cycle of Cultured Chinese Hamster Cells. Radiat. Res. 1996; 29: 450–474
   Web of Science ®Google Scholar
• Liebmann J., Cook J. A., Fisher J., et al. In Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells. J. Natl. Cancer Inst. 1994; 86: 441–446
   PubMed Web of Science ®Google Scholar
• Minarik L., Hall E. J. Taxol in Combination with Acute and Low Dose Rate Irradiation. Radiother. Oncol. 1994; 32: 124–128
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Safran H., et al. Multi-institutional Phase II Trial of Paclitaxel, Carboplatin and Concurrent Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. J. Clin. Oncol. 1998; 16: 3316–3322
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Safran H., et al. A Phase I Trial of Concurrent Weekly Taxol Administered as a 3 Hour Infusion and Radiation Therapy for Advanced Non-Small Cell Lung Cancer. J. Clin. Oncol. 1994; 12: 2682–2686
   PubMed Web of Science ®Google Scholar
• Costa F., Ilson D., Forastiere A., et al. Phase II Study of Paclitaxel and Cisplatin in Patients with Advanced Adenocarcinoma (A) and Squamous Cell (S) Carcinoma of the Esophagus. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: 262a
   Google Scholar
• Gupta N., Hu L. J., Deen D. F. Cytotoxicity and Cell-Cycle Effects of Paclitaxel When Used as a Single Agent and in Combination with Ionizing Radiation. Int. J. Rad. Oncol. Biol. Phys. 1997; 37: 885–895
   PubMed Web of Science ®Google Scholar
• Saito Y., Milross C. G., Hittelman W. N., et al. Effect of Radiation and Paclitaxel on p53 Expression in Murine Tumors Sensitive or Resistant to Apoptosis Induction. Int. J. Radiat. Oncol. Biol. Phys. 1997; 38: 623–631
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Bodis S., McClatchey A., et al. p53 Status and the Efficacy of Cancer Therapy In Vivo. Science 1994; 266: 807–810
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Ruley H. E., Jacks T. p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents. Cell 1993; 74: 957–967
   PubMed Web of Science ®Google Scholar
• Deisseroth A. B., DeVita V. T. The Cell Cycle. Probing New Molecular Determinants of Resistance and Sensitivity to Cytotoxic Agents. Cancer J. Sci. Am. 1995; 1: 15–21
   PubMedGoogle Scholar
• O'Connor P. M., Jackman J., Bae I., et al. Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth-Inhibitory Potency of 123 Anticancer Agents. Cancer Res. 1997; 57: 4285–4300
   PubMed Web of Science ®Google Scholar
• Wahl A. F., Donaldson K. L., Fairchild C., et al. Loss of Normal p53 Function Confers Sensitization to Taxol by Increasing G2/M Arrest and Apoptosis. Nature Med. 1996; 2: 72–79
   PubMed Web of Science ®Google Scholar
• Safran H., King T., Choy H., et al. p53 Mutations Do Not Predict Response to Paclitaxel/Radiation for Non-Small Cell Lung Cancer. Cancer 1996; 78: 1209–1216
   Web of Science ®Google Scholar
• Mason K. A., Milas L., Peters L. J. Effect of Paclitaxel (Taxol) Alone and in Combination with Radiation of the Gastrointestinal Mucosa. Int. J. Rad. Oncol. Biol. Phys. 1995; 32: 1381–1389
   PubMed Web of Science ®Google Scholar
• Glantz M. J., Choy H., Kearns C. M., et al. Phase I Study of Weekly Outpatient Paclitaxel and Concurrent Cranial Irradiation in Adults with Astrocytomas. J. Clin. Oncol. 1996; 14: 600–609
   PubMed Web of Science ®Google Scholar
• Wanebo H. J., Chougule P., Akerley W., et al. Preoperative Paclitaxel, Carboplatin and Radiation in Advanced Head and Neck Cancer (Stage III and IV) Induces a High Rate of Complete Pathologic Response (CR) at the Primary Site and High Rate of Organ Preservation. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: 391a
   Google Scholar
• Bates B. A., Detterbeck F. C., Bernard S. A., et al. Concurrent Radiation Therapy and Chemotherapy Followed by Esophagectomy for Localized Esophageal Carcinoma. J. Clin. Oncol. 1996; 14: 156–163
   PubMed Web of Science ®Google Scholar
• Ganem G., Dubray B., Raoul Y., et al. Concomitant Chemoradiotherapy Followed, Where Feasible, by Surgery for Cancer of the Esophagus. J. Clin. Oncol. 1997; 15: 701–711
   PubMed Web of Science ®Google Scholar
• Bosset J. F., Gignoux M., Triboulet J. P., et al. Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus. N. Engl. J. Med. 1997; 337: 161–167
   PubMed Web of Science ®Google Scholar
• Forastiere A. A., Orringer M. B., Perez-Tamayo C., et al. Preoperative Chemoradiation Followed by Transhiatal Esophagectomy for Carcinoma of the Esophagus: Final Report. J. Clin. Oncol. 1993; 11: 1118–1123
   PubMed Web of Science ®Google Scholar
• Lynch T. J., Choi N., Wright C., et al. A Phase I/II of Preoperative Taxol (T), Cisplatin (P), 5-FU (F) and Concurrent Boost Radiation (XRT) in Esophageal Cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: A261
   Google Scholar
• Meluch A. A., Hainsworth J. D., Gray J. R., et al. Preoperative Therapy with Paclitaxel, Carboplatin, 5-FU and Radiation in the Treatment of Local Esophageal Cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1998; 17: 259a
   Google Scholar
• Ajani J. A. Contributions of Chemotherapy in the Treatment of Carcinoma of the Esophagus: Results and Commentary. Semin. Oncol. 1994; 21: 474–482
   PubMed Web of Science ®Google Scholar
• Enzinger P., Ilson D., Minsky B., et al. Phase I/II Neoadjuvant Concurrent 96 Hour Taxol, Cisplatin, and Radiation Therapy: Promising Toxicity Profile and Response in Localized Esophageal Cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1999; 18: 271a
   Google Scholar
• Kelsen D., Ilson D., Lipton D., et al. A Phase I Trial of Radiation Therapy (Rt) Plus Concurrent Fixed Dose Cisplatin (C) with Escalating Doses of Paclitaxel (P) as a 96 Hour Continuous Infusion in Patients (Pts) with Localized Esophageal Cancer (EC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1999; 18: 271a
   Google Scholar
• Butera J., Malachovsky M., Rathore R., et al. Novel Approaches in Development for the Treatment of Pancreatic Cancer. Front. Bioscience 1998; 3: e226–229
   PubMedGoogle Scholar